FRA
ALXN

Front Row Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Front Row Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-32
Closed -$4K – 1049
2019
Q2 		$4K Hold
32
– – ﹤0.01% 694
2019
Q1 		$4K Hold
32
– – ﹤0.01% 685
2018
Q4 		$3K Hold
32
– – ﹤0.01% 741
2018
Q3 		$4K Hold
32
– – ﹤0.01% 646
2018
Q2 		$4K Buy
+32
New +$3.74K ﹤0.01% 708

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Front Row Advisors's ALXN Position: Q3 2019 in Review

Front Row Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2019, closing a stake of 32 shares — an estimated $4K sold.

Front Row Advisors first reported a position in ALXN in Q2 2018 and held it in 5 quarters. The position peaked at $4K in Q2 2019. 648 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

  • Front Row Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Front Row Advisors sold 32 Alexion Pharmaceuticals shares in Q3 2019, an estimated $4K.
  • Front Row Advisors first reported a position in Alexion Pharmaceuticals in Q2 2018 and held it in 5 quarters.
  • Front Row Advisors's Alexion Pharmaceuticals position peaked at $4K in Q2 2019.
  • 648 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Front Row Advisors's 13F filing for Q3 2019, filed 8 Nov 2019.